Physician profile
Oliver Gregory
NPI 1588772545
$12,913.60
in general payments reported to CMS, 2019-2025
35 companies · $3,129 in 2025
The $3,129 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $973 · 2021: $2,062 · 2022: $1,805 · 2023: $2,181 · 2024: $2,036 · 2025: $3,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,346.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,346.89 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,275.95 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,211.40 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,092.66 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,065.93 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $848.85 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $832.14 | 2021-2025 | |
| Lundbeck LLC | $690.07 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $540.59 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $538.99 | 2023-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $440.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $422.34 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $399.44 | 2019-2025 | Trintellix |
| Corium, LLC | $343.29 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $312.48 | 2023-2025 | Auvelity, Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $245.23 | 2020-2021 | |
| Bausch Health US, LLC | $231.89 | 2019-2024 | Aplenzin |
| Jazz Pharmaceuticals INC. | $217.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $174.27 | 2019-2023 | Belsomra |
| Allergan, INC. | $151.70 | 2019-2020 | |
| Adlon Therapeutics L.P. | $99.83 | 2019-2021 | |
| Neos Therapeutics, Lp | $67.48 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $58.57 | 2023 | Quviviq |
| Almatica Pharma LLC | $47.53 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $42.24 | 2024 | Secuado, Xelstrym |
| Brainsway USA INC | $34.30 | 2020-2024 | Brainsway Deep Tms System |
| Luye Pharma (USA) Ltd. | $29.42 | 2025 | Erzofri Extended-Release |
| Shire North American Group INC | $25.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.70 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.85 | 2025 | Rejoyn |
| Indivior INC. | $19.63 | 2022 | |
| Harmony Biosciences LLC | $18.44 | 2023 | Wakix |
| Acadia Pharmaceuticals INC | $18.29 | 2023 | Nuplazid |
| Tris Pharma INC | $17.92 | 2023 | Dyanavel Xr |
| Neuronetics, INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.